The immune checkpoint blockade (ICB) therapy, which specifically targets the cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or its ligands (PD-L1), has been used for cancer immunotherapy and has shown promising clinical results (19). Here, PDCD1 is linked to cancer.